Dual Benefit of TGF Inhibition on Tumor Control in the Context of Radiotherapy for Breast Cancer Brain Metastases
Technical Report,01 Feb 2017,31 Jan 2019
The Regents of the University of California, San Francisco San Francisco United States
Pagination or Media Count:
This project evaluates whether transforming growth factor beta TGF inhibition during radiation therapy RT to breast cancer brain metastases BCBM provides greater therapeutic benefit than RT alone using a robust proof-of-concept therapeutic protocol in combination with innovative functional imaging. Successful demonstration that TGF inhibition increases durable RT response that may augment immunotherapy in preclinical BCBM models would provide a strong rationale for trials of clinically viable drugs that block TGF signaling with gamma-knife stereotactic radiosurgery GKSRS for women with metastatic disease. We incorporate molecular imaging of active TGF to assess target levels, drug delivery, therapeutic response via tumor metabolism, and identify potential immune mediated responses that will enable rapid clinical translation of combined RT and TGF inhibitory drug regimens.
- Medicine and Medical Research